LU92782I2 - Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson - Google Patents

Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson Download PDF

Info

Publication number
LU92782I2
LU92782I2 LU92782C LU92782C LU92782I2 LU 92782 I2 LU92782 I2 LU 92782I2 LU 92782 C LU92782 C LU 92782C LU 92782 C LU92782 C LU 92782C LU 92782 I2 LU92782 I2 LU 92782I2
Authority
LU
Luxembourg
Prior art keywords
safinamide
levodopa
pdi
parkinson
drugs
Prior art date
Application number
LU92782C
Other languages
English (en)
French (fr)
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92782(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Publication of LU92782I2 publication Critical patent/LU92782I2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU92782C 2003-04-11 2015-07-22 Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson LU92782I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46220503P 2003-04-11 2003-04-11

Publications (1)

Publication Number Publication Date
LU92782I2 true LU92782I2 (fr) 2015-09-22

Family

ID=33159845

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92782C LU92782I2 (fr) 2003-04-11 2015-07-22 Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson

Country Status (28)

Country Link
US (3) US8283380B2 (de)
EP (2) EP1613296B1 (de)
JP (2) JP2006522800A (de)
KR (2) KR20110070929A (de)
CN (2) CN1771030A (de)
AR (1) AR044007A1 (de)
AT (1) ATE435012T1 (de)
AU (1) AU2004228782B2 (de)
BR (1) BRPI0409364A (de)
CA (1) CA2523188C (de)
CY (3) CY1109295T1 (de)
DE (1) DE602004021790D1 (de)
DK (2) DK1613296T3 (de)
ES (2) ES2454272T3 (de)
FR (1) FR15C0054I2 (de)
HU (1) HUS1500043I1 (de)
IL (2) IL171331A (de)
LU (1) LU92782I2 (de)
MX (1) MXPA05010873A (de)
NL (1) NL300752I2 (de)
NO (3) NO334316B1 (de)
NZ (1) NZ542910A (de)
PL (2) PL2070526T3 (de)
PT (2) PT2070526E (de)
RU (1) RU2342929C2 (de)
SI (2) SI1613296T1 (de)
TW (1) TWI340640B (de)
WO (1) WO2004089353A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
PT1423168E (pt) 2001-09-03 2006-05-31 Newron Pharm Spa Composicao farmaceutica que compreende gabapentina ou um seu analogo e uma x-aminoamida e a sua utilizacao como analgesico
EP1438956A1 (de) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-Aminoamidderivate die als Antimigränemittel nützlich sind
EP1658062B1 (de) * 2003-08-25 2010-02-17 Newron Pharmaceuticals S.p.A. Alpha-aminoamid derivate zur verwendung als anti-inflammatorische wirkstoffe
EP1588704A1 (de) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamidderivate zur Behandlung des Restless-Leg-Syndroms und der Suchterkrankungen
CN101018546B (zh) * 2004-09-10 2013-06-12 纽朗制药有限公司 作为钠和/或钙通道选择性调节剂的(卤代苄氧基)苄氨基-丙酰胺类
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
WO2007069274A2 (en) * 2005-11-09 2007-06-21 Torrent Pharmaceuticals Limited Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
SI1963280T1 (sl) * 2005-12-22 2016-02-29 Newron Pharmaceuticals S.P.A. 2-feniletilamino derivati kot modulatorji kalcijevih in/ali natrijevih kanalčkov
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1870097A1 (de) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamidederivate zur Behandlung von kognitiven Störungen
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
EA017123B1 (ru) * 2006-06-19 2012-10-30 Ньюрон Фармасьютикалс С.П.А. Способ получения 2-[4-(3- и 2-фторбензилокси)бензиламино]пропанамидов
DE102007014947B4 (de) * 2007-03-23 2010-05-27 Axxonis Pharma Ag Stabilisierte wässrige Lösungen von Ergolinverbindungen
CA2684550A1 (en) * 2007-04-24 2008-10-30 Boehringer Ingelheim International Gmbh Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US8519000B2 (en) 2007-06-15 2013-08-27 Newron Pharmaceuticals S.P.A. Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
GB2453770A (en) * 2007-10-19 2009-04-22 Reckitt Benckiser Healthcare Oral composition comprising a cooling agent
US20090149544A1 (en) * 2007-10-22 2009-06-11 Concert Pharmaceuticals, Inc. Alpha-aminoamide derivatives
HUE036232T2 (hu) 2007-12-11 2018-06-28 Newron Pharm Spa Eljárás nagy tisztasági fokú 2-[4-(3- vagy 2-fluorbenziloxi)-benzilamino]- propánamidok elõállítására
CN101903021B (zh) * 2007-12-19 2012-11-14 纽朗制药有限公司 用于治疗精神病的α-氨基酰胺衍生物
WO2009122351A2 (en) * 2008-04-01 2009-10-08 Kangwon National University Anti-parkinsonian compounds mppe
CA2723870C (en) * 2008-06-02 2015-04-21 Generics [Uk] Limited An improved process for the preparation of amines
CA2723869C (en) 2008-06-02 2013-07-16 Generics [Uk] Limited A process for the preparation of enantiomerically pure amines
PL2303330T5 (pl) * 2008-06-06 2021-10-25 Pharma Two B Ltd. Kompozycje farmaceutyczne do leczenia choroby Parkinsona
JP2011522892A (ja) * 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
WO2010010138A1 (en) * 2008-07-24 2010-01-28 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease
US20100189790A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
EP2218444A3 (de) * 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Rasagilinformulierung mit verzögerter Freisetzung
EP2314569A1 (de) 2009-10-22 2011-04-27 Merck Patent GmbH Neuartige polymorphe Formen von (S)-2-[4-(3-Fluor-benzyloxy)-benzylamino]-Propionamidmesylatsalz und Herstellungsverfahren dafür
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
WO2011098456A1 (en) 2010-02-09 2011-08-18 Merck Serono S.A. Safinamide in the treatment of dyskinesia
EA021389B1 (ru) 2010-04-27 2015-06-30 Ньюрон Фармасьютикалс С.П.А. Способ получения метансульфонатных солей ралфинамида или их r-энантиомеров
UA103851C2 (en) 2010-04-30 2013-11-25 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Propylaminoindan transdermal composition
EP2688561B1 (de) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Transdermale zusammensetzungen mit einer wirkstoffschicht und einer wirkstoffumwandlungsschicht
US20150031768A1 (en) * 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
WO2013081685A1 (en) 2011-08-19 2013-06-06 The Trustees Of Princeton University C-halogen bond formation
EP2776020B1 (de) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Verfahren zur behandlung von neoplasmen der haut
EA031621B1 (ru) 2012-11-02 2019-01-31 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Трансдермальная композиция на основе пропиниламиноиндана, содержащий такие композиции набор и способ доставки пропиниламиноиндана
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
EP3013342B1 (de) 2013-06-27 2021-04-14 Cedars-Sinai Medical Center Adrenorezeptor-antagonisten zur vorbeugung und behandlung neurodegenerativer erkrankungen
EP3831375A1 (de) * 2014-04-21 2021-06-09 Civitas Therapeutics, Inc. Schnelle linderung von motorischen fluktuationen bei morbus parkinson
CN106795098B (zh) * 2014-10-02 2020-07-14 默加拜奥伍德有限公司 α-氨基酰胺衍生化合物及包含其的药物组合物
MX2018002255A (es) * 2015-08-27 2018-06-06 Prexton Therapeutics Sa Derivado de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levodopa.
EP3429569A4 (de) * 2016-03-17 2020-02-26 The Johns Hopkins University Verfahren zur vorbeugung oder behandlung der parkinson-krankheit durch die farnesylierung von paris
ITUA20163981A1 (it) 2016-05-31 2017-12-01 Zambon Spa Composizioni farmaceutiche comprendenti safinamide
EP3568082A4 (de) * 2017-01-14 2020-12-09 Neurrx, SPC Verfahren zur verwendung menschlicher exkremente und sekrete zur früherkennung von morbus parkinson
CN109251155A (zh) * 2017-07-14 2019-01-22 广东东阳光药业有限公司 α-氨基酰胺衍生物及其用途
WO2019036624A1 (en) * 2017-08-17 2019-02-21 Gu Zi Qiang MONOAMINE PAMOATE SALT TYPE ANTI-PARKINSON AGENTS, PROCESS FOR PREPARING AND USING SAME
BR112020008653A2 (pt) 2017-11-02 2020-10-27 Zambon S.P.A. composições farmacêuticas compreendendo safinamida
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
CN110938014A (zh) * 2019-11-28 2020-03-31 岳千奥 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
JP2023504876A (ja) * 2019-12-06 2023-02-07 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 薬物組成物、キット及びその応用
CN110999980A (zh) * 2019-12-19 2020-04-14 新疆石河子职业技术学院（石河子市技工学校） 一种葡萄酒洗浸奶酪加工方法
EP4203939A1 (de) * 2020-08-31 2023-07-05 Purdue Pharma L.P. Zusammensetzungen und verfahren zur levodopa-freisetzung

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US4049663A (en) 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4935429A (en) 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
ATE76747T1 (de) * 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
JP2736103B2 (ja) 1988-03-01 1998-04-02 ヴァルター・ビルクマイヤー パーキンソン症候群の治療用医薬、およびその製造方法
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5502658A (en) 1990-12-27 1996-03-26 Relin; Arkadi Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
PT828513E (pt) * 1995-05-26 2004-05-31 Pfizer Combinacoes contendo antagonistas selectivos de nmda para o tratamento do parkinsonismo
GB9515412D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
FR2829027A1 (fr) * 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson

Also Published As

Publication number Publication date
PT2070526E (pt) 2014-03-31
NO20054640L (no) 2005-12-09
US20070093495A1 (en) 2007-04-26
JP2006522800A (ja) 2006-10-05
IL171331A (en) 2012-03-29
JP2013067647A (ja) 2013-04-18
EP1613296B1 (de) 2009-07-01
SI2070526T1 (sl) 2014-05-30
PL1613296T3 (pl) 2009-12-31
PL2070526T3 (pl) 2014-08-29
US8901176B2 (en) 2014-12-02
CY2015025I1 (el) 2016-04-13
ATE435012T1 (de) 2009-07-15
KR101129015B1 (ko) 2012-04-20
NL300752I2 (de) 2016-07-05
EP2070526B1 (de) 2014-02-26
RU2005131422A (ru) 2006-04-27
WO2004089353A3 (en) 2004-12-16
ES2326373T3 (es) 2009-10-08
TW200505423A (en) 2005-02-16
NO335537B1 (no) 2014-12-22
US8283380B2 (en) 2012-10-09
CN1771030A (zh) 2006-05-10
CY1109295T1 (el) 2014-07-02
DK2070526T3 (da) 2014-03-24
KR20060010745A (ko) 2006-02-02
WO2004089353A2 (en) 2004-10-21
PT1613296E (pt) 2009-07-30
KR20110070929A (ko) 2011-06-24
NO2015018I1 (no) 2015-08-03
IL216403A0 (en) 2011-12-29
IL216403A (en) 2015-01-29
NO20131417L (no) 2005-12-09
CN102274517A (zh) 2011-12-14
NO20054640D0 (no) 2005-10-10
MXPA05010873A (es) 2006-03-21
US9492410B2 (en) 2016-11-15
NZ542910A (en) 2007-10-26
CN102274517B (zh) 2018-08-31
US20150150833A1 (en) 2015-06-04
CA2523188C (en) 2012-09-25
NO334316B1 (no) 2014-02-03
NO2015018I2 (no) 2015-07-23
AU2004228782B2 (en) 2010-05-20
CY1115286T1 (el) 2017-01-04
DE602004021790D1 (de) 2009-08-13
ES2454272T3 (es) 2014-04-10
WO2004089353A8 (en) 2005-09-01
DK1613296T3 (da) 2009-10-05
SI1613296T1 (sl) 2009-10-31
RU2342929C2 (ru) 2009-01-10
AU2004228782A1 (en) 2004-10-21
BRPI0409364A (pt) 2006-04-25
US20130053368A1 (en) 2013-02-28
CY2015025I2 (el) 2016-04-13
AR044007A1 (es) 2005-08-24
TWI340640B (en) 2011-04-21
CA2523188A1 (en) 2004-10-21
FR15C0054I1 (fr) 2015-11-09
EP2070526A1 (de) 2009-06-17
HUS1500043I1 (hu) 2018-11-28
EP1613296A2 (de) 2006-01-11
FR15C0054I2 (fr) 2018-01-26

Similar Documents

Publication Publication Date Title
LU92782I2 (fr) Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson
PT1446122E (pt) Utilizacao de flibanserina no tratamento de disturbios de desejo sexual
FR2886851B1 (fr) Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
WO2005034998A3 (en) Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1769791A3 (de) Therapeutische strategien für die prävention und behandlung der alzeheimer-krankheit
GB0404693D0 (en) Pharmaceutical preparations for the treatment of ocular surface and other disorders
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
EP1676512A3 (de) Artikel zum behandeln der Haut und Verfahren
PL1656372T3 (pl) Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
ZA200802897B (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's Disease
EA200700427A1 (ru) Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
WO2004069146A3 (en) L-dopa amide derivatives and uses thereof
ITRM20050446A1 (it) Uso di stilbeni idrossilati e glucosidati per la prevenzione ed il trattamento di patologie oculari.
EP2035412A4 (de) Muskarinrezeptoragonisten, die bei der behandlung von schmerzen, alzheimer-krankheit und schizophrenie effektiv sind
FR2886850B1 (fr) Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
IL185300A0 (en) New pharmaceutical compositions useful in the treatment of parkinson's disease
BRPI0811538A2 (pt) Uso de ciclosporinas no tratamento de pacientes com lentes intraoculares.
FR2866340B1 (fr) Derives d'oxazole, leur preparation et leur utilisation en therapeutique.
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
IL195441A0 (en) Use of trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine and its formamide in the preparation of medicaments for the treatment of pain disorders
PL378360A1 (pl) Sposób leczenia choroby Parkinsona u ludzi za pomocą infuzji do skorupy czynnika neurotroficznego pochodzącego z gleju
FR2886852B1 (fr) Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
DZ3141A1 (fr) Inhibiteurs d'aminotransferase acides aminés-dépendante à chaîne ramifiée, et leur utilisation dans le cadre du traitement de la rétinopathie diabétique.
WO2006012521A3 (en) Treatment for ocular disease
HK1097762A1 (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients